Status:
TERMINATED
A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This study will assess the pharmacokinetics of MK-0941 in participants with varying degrees of renal insufficiency.
Eligibility Criteria
Inclusion
- Male or nonpregnant female age 18 to 75 years
- Female of childbearing potential on appropriate method of contraception
- Body mass index (BMI) less than or equal to 40 kg/m2
- Participant is in good health
- Participant diagnosed with Type 2 Diabetes
- Participant agrees to follow smoking restrictions
- Willing to follow the study diet restrictions
Exclusion
- Mental or legal incapacitation
- Participant has had kidney removed
- History of Type 1 diabetes
- History of stroke, chronic seizures or major neurological disorder
- History of neoplastic disease
- Nursing mother
- Consumes greater than 4 glasses of alcoholic beverages per day
- Consumes greater than 6 servings of caffeinated beverages per day
- Participant has had surgery or donated 1 unit of blood within 1 month of screening
- Participant has history of recent eye infection within 2 weeks of study drug administration
- Clinically diagnosed with glaucoma or blindness
- Has trauma to one or both eyes
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00830791
Start Date
January 1 2009
End Date
September 1 2009
Last Update
February 26 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.